Accuray (ARAY) Projected to Post Quarterly Earnings on Wednesday

Accuray (NASDAQ:ARAY) is expected to release its Q2 2026 results after the market closes on Wednesday, February 4th. Analysts expect Accuray to post earnings of ($0.11) per share and revenue of $100.86 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 4:30 PM ET.

Accuray (NASDAQ:ARAY) last issued its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.13). Accuray had a negative return on equity of 34.06% and a negative net margin of 4.28%.The company had revenue of $93.94 million during the quarter, compared to analyst estimates of $91.34 million. On average, analysts expect Accuray to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Accuray Price Performance

NASDAQ ARAY opened at $0.80 on Tuesday. Accuray has a 12 month low of $0.78 and a 12 month high of $2.95. The firm has a market capitalization of $90.83 million, a PE ratio of -5.01 and a beta of 1.15. The company’s 50 day simple moving average is $0.91 and its 200 day simple moving average is $1.27. The company has a debt-to-equity ratio of 2.06, a current ratio of 1.56 and a quick ratio of 0.76.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Wall Street Zen upgraded Accuray from a “sell” rating to a “hold” rating in a research report on Monday, January 5th. BTIG Research dropped their price target on shares of Accuray from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, November 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Accuray in a research report on Monday, December 29th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $4.00.

Hedge Funds Weigh In On Accuray

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. raised its stake in Accuray by 52.3% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 523,145 shares of the medical equipment provider’s stock valued at $874,000 after purchasing an additional 179,745 shares during the period. Armistice Capital LLC grew its holdings in shares of Accuray by 2.7% during the third quarter. Armistice Capital LLC now owns 3,324,000 shares of the medical equipment provider’s stock valued at $5,551,000 after buying an additional 88,000 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new position in shares of Accuray during the third quarter valued at $35,000. Citadel Advisors LLC raised its position in Accuray by 9,301.4% during the third quarter. Citadel Advisors LLC now owns 662,499 shares of the medical equipment provider’s stock valued at $1,106,000 after buying an additional 669,699 shares during the period. Finally, Ameriprise Financial Inc. purchased a new stake in Accuray in the 3rd quarter worth about $73,000. Institutional investors and hedge funds own 64.08% of the company’s stock.

About Accuray

Accuray Incorporated (NASDAQ: ARAY) is a global medical device company that develops, manufactures and markets innovative radiation therapy solutions for the treatment of cancer. The company’s flagship products include the CyberKnife® System, a robotic radiosurgery platform offering sub-millimeter precision, and the TomoTherapy® System, which combines helical computed tomography (CT) imaging with intensity-modulated radiation therapy (IMRT). More recently, Accuray introduced the Radixact® System, an advanced iteration of its TomoTherapy technology designed to enhance treatment speed and clinical workflow.

Accuray’s suite of products enables clinicians to deliver highly targeted radiation doses while minimizing exposure to surrounding healthy tissue.